Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET

Key facts

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.

Principal Investigator

Rong Li, Doctor

Peking University Third Hospital

Intervention

Triptorelin for Injection(drug)

Enrollment

252 target

Eligibility

20-39 years · FEMALE

Timeline

2017 – 2018

Study locations (7)

• The first Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
• Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
• The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
• Xiangya Hospital Central South University, Changsha, Hunan, China
• Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
• Peking University Third Hospital, Beijing, China
• Jiangsu Province Hospital, Nanjing, China

Collaborators

Peking University Third Hospital · The First Affiliated Hospital with Nanjing Medical University · Women's Hospital School Of Medicine Zhejiang University · Xiangya Hospital of Central South University · Sixth Affiliated Hospital, Sun Yat-sen University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · The First Affiliated Hospital of Anhui Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07043322
  Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
  Tanta University

See all trials for Ovarian hyperstimulation syndrome →